References

This detects tumor signal at lower ctDNA levels while reducing interference from clonal hematopoiesis.

Guardant Infinity is for Research Use Only. Not for use in diagnostic procedures

InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.

Methylation-based detection identifies and quantifies tumor signals in late-stage cancers with as low as 0.001% circulating tumor fraction (TF)

Home‍Guardant Infinity™ for BioPharma‍ ‍Guardant360® CDx for BioPharma‍ ‍InfinityAI for BioPharma

QUANTIFY CANCER

Methylation-based tumor fraction dramatically improves sensitivity in cancer monitoring compared with genomic signals alone.¹